Drugs & Targets FDA, FTC collaborate to deter anti-competitive practices involving biosimilars February 07, 2020Vol.46 No.06
Drugs & Targets Predictive Technology Group and Atrin Pharmaceuticals collaborate on molecular diagnostic oncology development January 31, 2020Vol.46 No.5
Drugs & Targets FDA grants Tazverik accelerated approval as first treatment option for epithelioid sarcoma January 24, 2020Vol.46 No.04
Drugs & Targets FDA grants priority review of belantamab mafodotin for relapsed or refractory multiple myeloma January 24, 2020Vol.46 No.04
Drugs & Targets Myriad submits sPMA for BRACAnalysis CDx as companion diagnostic for Lynparza in metastatic castration-resistant prostate cancer January 24, 2020Vol.46 No.04
Drugs & Targets Health Canada approves Keytruda + Inlyta for advanced RCC January 24, 2020Vol.46 No.04
Drugs & Targets 9/11 responders have increased overall cancer incidence in thyroid, prostate, and leukemia cancers, study finds January 24, 2020Vol.46 No.04
Drugs & Targets FDA grants Rubraca Priority Review for advanced prostate cancer January 17, 2020Vol.46 No.03
Drugs & Targets FDA accepts BLA for Priority Review of Opdivo + Yervoy in first-line NSCLC January 17, 2020Vol.46 No.03
